BioSante Pharmaceuticals Inc. has entered an agreement with Azur Pharma Ltd. to market Elestrin (estradiol gel) in the U.S. to treat moderate-to-severe hot flashes in menopausal women, a deal that could bring in up to $144.5 million for BioSante plus double-digit royalties. (BioWorld Today)